Immune Response News and Research

RSS

Influenza virus can change microRNA expression to control immune responses in human lung cells

When you are hit with the flu, you know it immediately -- fever, chills, sore throat, aching muscles, fatigue. This is your body mounting an immune response to the invading virus. But less is known about what is happening on the molecular level.

24 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

Aeras, IDRI announce start of first ID93 + GLA-SE Phase I trial for tuberculosis

Aeras and the Infectious Disease Research Institute (IDRI) announce today the start of the first clinical trial of IDRI's novel tuberculosis vaccine candidate, ID93 + GLA-SE.

23 Aug 2012

New silicon chips help identify patients with lupus

Researchers at the Stanford University School of Medicine and Intel Corp. have collaborated to synthesize and study a grid-like array of short pieces of a disease-associated protein on silicon chips normally used in computer microprocessors.

21 Aug 2012

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) announced today successful results from two programs of work carried out by French partner VIVALIS (NYSE Euronext: VLS), confirming the ability of BioDiem’s Live Attenuated Influenza Virus (LAIV) to grow in VIVALIS’ proprietary EB66® cell line.

20 Aug 2012

New book on malaria tells story of Plasmodium falciparum Genome Project

Few infectious diseases can rival malaria's ability to kill and cripple. Each year the disease causes hundreds of millions of people to be sickened and more than a million - mostly African children under the age of five - die.

18 Aug 2012

FibeBiotics aims to prove benefits of polysaccharides in clinical trials

Staying healthy requires constantly stimulating the immune system. Ingesting non-digestible fibres such as polysaccharides is thought to help. Yet companies including such ingredients in their food products cannot claim that they boost the immune system. At least, not until they have been scientifically tested and proven in clinical trials. Only then, would the European Food Safety Agency (EFSA) allow such health claims.

18 Aug 2012

Diabetes Research Institute to receive JDRF-HCT grant for islet encapsulation study

JDRF, in collaboration with The Leona M. and Harry B. Helmsley Charitable Trust (HCT), announced today that it has finalized a grant in the area of islet cell encapsulation to Dr. Camillo Ricordi, M.D. and a team of investigators at the Diabetes Research Institute (DRI), based at the University of Miami (FL).

17 Aug 2012

Combination of Zelboraf and immunotherapy increases tumor responses and survival in MM

Combining the recently approved BRAF inhibitor, Zelboraf with an engineered T cell immunotherapy to treat metastatic melanoma significantly increased tumor responses and survival in an animal model, researchers at UCLA's Jonsson Comprehensive Cancer Center have shown.

16 Aug 2012

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.

16 Aug 2012

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

An experimental immune-based therapy more than doubled median survival of patients diagnosed with the most aggressive malignant brain tumor, Cedars-Sinai Medical Center researchers reported in Cancer Immunology, Immunotherapy, published online Aug. 3.

16 Aug 2012

Addiction to morphine and heroin can be blocked via brain's immune response

In a major breakthrough, an international team of scientists has proven that addiction to morphine and heroin can be blocked, while at the same time increasing pain relief.

15 Aug 2012

Researchers identify key element in the development of Burkitt lymphoma

Burkitt lymphoma is a malignant, fast-growing tumor that originates from a subtype of white blood cells called B lymphocytes of the immune system and often affects internal organs and the central nervous system. Now Dr. Sandrine Sander and Professor Klaus Rajewsky of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have identified a key element that transforms the immune cells into malignant lymphoma cells.

14 Aug 2012

Researchers solve hepatitis C vaccine mystery

Researchers at the Burnet Institute have solved a hepatitis C vaccine mystery which, once developed could be the first ever preventative vaccine for the virus.

13 Aug 2012

New clinical trial to study how worm eggs may relieve symptoms of ulcerative colitis

A new clinical trial designed to study how worm eggs may relieve symptoms of ulcerative colitis (UC) will begin enrolling patients at NYU School of Medicine's Clinical and Translational Science Institute. This unusual therapy has been used in previous clinical trials on patients with inflammatory bowel diseases, but the mechanism of action is unclear.

8 Aug 2012

BioDiem granted European patent for antimicrobial drug

Australian vaccine development company BioDiem Ltd (ASX: BDM) announced today the successful granting of a key European patent for its synthetic antimicrobial compound BDM-I. BDM-I is a novel compound active against a range of pathogenic micro-organisms including bacteria, fungi and protozoa. The patent provides protection around BDM-I as a treatment for vulvovaginitis, a general term for inflammation of the vulva or vagina.

7 Aug 2012

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

BioDiem recently signed a collaborative agreement with The Royal Melbourne Institute of Technology (RMIT) for the development of non-influenza vaccines using BioDiem’s proprietary live attenuated influenza virus (LAIV) technology.

7 Aug 2012

Blood levels of IL-6 protein may also serve as red flag for relapse in schizophrenia patients

Blood levels of a protein that helps regulate inflammation may also serve as a red flag for relapse in some schizophrenia patients, researchers said.

7 Aug 2012

Previously uncharacterized protein dramatically influences inflammation

A UNC-led team of scientists describes the function of a previously uncharacterized protein that dramatically influences inflammation.

6 Aug 2012

Allergies may reduce risk of brain cancer

New research adds to the growing body of evidence suggesting that there's a link between allergies and reduced risk of a serious type of cancer that starts in the brain. This study suggests the reduced risk is stronger among women than men, although men with certain allergy profiles also have a lower tumor risk.

3 Aug 2012

Immune Response News and Research

Influenza virus can change microRNA expression to control immune responses in human lung cells

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Aeras, IDRI announce start of first ID93 + GLA-SE Phase I trial for tuberculosis

New silicon chips help identify patients with lupus

BioDiem and French partner VIVALIS a step forward in developing vaccines for diseases and related cancers

New book on malaria tells story of Plasmodium falciparum Genome Project

FibeBiotics aims to prove benefits of polysaccharides in clinical trials

Diabetes Research Institute to receive JDRF-HCT grant for islet encapsulation study

Combination of Zelboraf and immunotherapy increases tumor responses and survival in MM

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

Cedars-Sinai's ICT-107 doubles median survival of patients with malignant brain tumor

Addiction to morphine and heroin can be blocked via brain's immune response

Researchers identify key element in the development of Burkitt lymphoma

Researchers solve hepatitis C vaccine mystery

New clinical trial to study how worm eggs may relieve symptoms of ulcerative colitis

BioDiem granted European patent for antimicrobial drug

Creating new non-influenza vaccines: an interview with Julie Phillips, CEO of BioDiem

Blood levels of IL-6 protein may also serve as red flag for relapse in schizophrenia patients

Previously uncharacterized protein dramatically influences inflammation

Allergies may reduce risk of brain cancer

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News